Serotonin Reuptake Inhibitors and 5-HT1A Receptors
Serotonin Reuptake Inhibitors and 5-HT1A Receptors
批准号:
7163798
负责人:
GEORGE BATTAGLIA
金额:
$32.45万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-09-30 至 2009-05-31
关键词:
8-Hydroxy-2-(di-n-propylamino)tetralinAddressAdenovirusesAgonistAmygdaloid structureAnti-Anxiety AgentsAntidepressive AgentsBindingBinding SitesBiochemicalBoxingCell NucleusCell membraneCell physiologyChronicClinicalCorticotropinCouplingCultured CellsDataDepthDiseaseElevationEvaluationFigs - dietaryFluoxetineFundingFutureGenesGenetic TranscriptionHandHumanHypothalamic structureInfusion proceduresInjection of therapeutic agentLeadMAP Kinase GeneMAP Kinase ModulesMEKsMediatingMessenger RNAMitogen-Activated Protein KinasesModelingMolecularMood DisordersNeurosecretory SystemsOxytocinPatientsPhosphorylationPhosphotransferasesPlasmaPlayPrincipal InvestigatorPromoter RegionsProtein BindingProteinsProzacPsychiatryRattusReceptor ActivationReceptor SignalingRecombinantsRegulationResearch PersonnelRoleSelective Serotonin Reuptake InhibitorSerotoninSerotonin Receptor 5-HT1ASignal TransductionSynapsesSystemTestingTherapeuticTherapeutic EffectTimeU-0126Weekbasec-myc Genesdaydesensitizationdorsal raphe nucleusdrug developmentin vivoinhibitor/antagonistneuropsychiatryparaventricular nucleuspreventproductivity lossprogramsreceptorreceptor densityresearch studyresponsesuicidal risktranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac/R) have revolutionized psychiatry. However, a major problem with SSRIs is a 2-3 week delay in therapeutic onset. Studies from the last funding period indicate that SSRIs produce a robust desensitization of hypothalamic post-synaptic serotonin lA (5-HT1A) receptors in rats. This desensitization has a gradual onset (7-14 days), corresponding with the 2-3 week delay in therapeutic effects of SSRIs. Hence, desensitization of post-synaptic 5-HTIA receptors could be a model of some of the therapeutic effects of SSRIs. The long delay in clinical improvement after the onset of SSRI treatment remains a fundamental problem that may be overcome by a more comprehensive understanding of the underlying basis for 5-HT1A receptor desensitization. Therefore this competitive renewal will focus on the mechanisms responsible for the homologous desensitization of post-synaptic hypothalamic 5-HTIA receptor systems during treatment of rats with SSRIs, The focus of this proposal is on the 5-HT1A receptor - Gz protein - mitogen-activated protein kinase (MAPK also known as ERK1/2) cascade. The MAP kinase cascade (Raf-MEK-ERK) is involved in many cellular processes including receptor desensitization. Our preliminary studies indicate that 5-HT1A-receptor activation produces a rapid phosphorylation of MAP kinase (ERK1/2) in the rat hypothalamic paraventricular nucleus. Our central hypothesis is that Gz protein-MAP kinase signaling mediates the desensitization of 5-HTIA receptors by SSRIs. Four specific aims are proposed: Specific Aim 1 will test the hypothesis that Gz proteins mediate the 5-HTIA receptor-mediated activation of MAP kinase signaling in the hypothalamus. Specific Aim 2 will test the hypothesis that reduced expression of Gz proteins mediates SSRI-induced desensitization of hypothalamic 5-HTIA receptors. Specific Aim 3 will test the hypothesis that MAP kinase signaling mediates the SSRI-induced desensitization of post-synaptic 5-HTIA receptors in the hypothalamus. Specific Aim 4 will identify the transcription factors (c-myc and Spl) that mediate fluoxetine-induced desensitization of 5-HTIA receptors. The proposed studies will provide an in-depth understanding of the regulation of post-synaptic 5-HTIA receptor signaling in vivo and will identify new targets for the treatment of mood disorders.
期刊论文(42)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Characterization of the functional heterologous desensitization of hypothalamic 5-HT(1A) receptors after 5-HT(2A) receptor activation.
5-HT(2A) 受体激活后下丘脑 5-HT(1A) 受体功能性异源脱敏的表征。
DOI:
10.1523/jneurosci.21-20-07919.2001
发表时间:
2001
期刊:
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子:
--
作者:
[Zhang,Y, D'Souza,D, Raap,DK, Garcia,F, Battaglia,G, Muma,NA, VandeKar,LD]
通讯作者:
VandeKar,LD
Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine(1A) receptors in hypothalamus.
5-羟色胺 (1A) 拮抗剂 WAY-100635 的共同给药可防止氟西汀诱导的下丘脑突触后 5-羟色胺 (1A) 受体脱敏。
DOI:
--
发表时间:
2000
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
[Serres,F, Muma,NA, Raap,DK, Garcia,F, Battaglia,G, VandeKar,LD]
通讯作者:
VandeKar,LD
Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist.
长期服用氟西汀会导致 5-HT1A 受体逐渐脱敏:下丘脑和中脑 Gi 和 G(o) 蛋白减少,以及对 5-HT1A 激动剂的神经内分泌反应减少。
DOI:
--
发表时间:
1996
期刊:
The Journal of pharmacology and experimental therapeutics.
影响因子:
--
作者:
[Li,Q, Muma,NA, vandeKar,LD]
通讯作者:
vandeKar,LD
DOI:
10.1080/10253890802046281
发表时间:
2009-01
期刊:
STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS
影响因子:
2.3
作者:
[Grippo, Angela J., Johnson, Alan Kim]
通讯作者:
Johnson, Alan Kim
Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI.
有证据表明下丘脑室旁核中的 5-HT2A 受体介导对 (-)DOI 的神经内分泌反应。
DOI:
10.1523/jneurosci.22-21-09635.2002
发表时间:
2002
期刊:
The Journal of neuroscience : the official journal of the Society for Neuroscience
影响因子:
--
作者:
[Zhang,Yahong, Damjanoska,KaterinaJ, Carrasco,GonzaloA, Dudas,Bertalan, D'Souza,DeborahN, Tetzlaff,Julie, Garcia,Francisca, Hanley,NicoleRSullivan, Scripathirathan,Kumar, Petersen,BrettR, Gray,ThackeryS, Battaglia,George, Muma,NancyA, ]
通讯作者:
共 19 条
Time Course and Potentiation of Fluoxetin Action
-
批准号:6692989
-
项目类别:
-
资助金额:$3.94万
-
财政年份:2002
-
负责人:GEORGE BATTAGLIA
-
依托单位:
TREATMENT OF COCAINE-INDUCED 5-HT DYSFUNCTION
-
批准号:6700844
-
项目类别:
-
资助金额:$33.3万
-
财政年份:2001
-
负责人:GEORGE BATTAGLIA
-
依托单位:
TREATMENT OF COCAINE-INDUCED 5-HT DYSFUNCTION
-
批准号:6846569
-
项目类别:
-
资助金额:$33.3万
-
财政年份:2001
-
负责人:GEORGE BATTAGLIA
-
依托单位:
PREPUBESCENT SSRIS & 5HT RECEPTOR SIGNALLING
-
批准号:6625433
-
项目类别:
-
资助金额:$27.55万
-
财政年份:1999
-
负责人:GEORGE BATTAGLIA
-
依托单位:
PREPUBESCENT SSRIS & 5HT RECEPTOR SIGNALLING
-
批准号:6031352
-
项目类别:
-
资助金额:$23.97万
-
财政年份:1999
-
负责人:GEORGE BATTAGLIA
-
依托单位:
PREPUBESCENT SSRIS & 5HT RECEPTOR SIGNALLING
-
批准号:6477105
-
项目类别:
-
资助金额:$26.75万
-
财政年份:1999
-
负责人:GEORGE BATTAGLIA
-
依托单位:
PREPUBESCENT SSRIS & 5HT RECEPTOR SIGNALLING
-
批准号:6330339
-
项目类别:
-
资助金额:$24.42万
-
财政年份:1999
-
负责人:GEORGE BATTAGLIA
-
依托单位:
Serotonin Reuptake Inhibitors and 5-HT1A Receptors
-
批准号:7009552
-
项目类别:
-
资助金额:$33.42万
-
财政年份:1995
-
负责人:GEORGE BATTAGLIA
-
依托单位:
Serotonin Reuptake Inhibitors and 5-HT1A Receptors
-
批准号:6726356
-
项目类别:
-
资助金额:$34.23万
-
财政年份:1995
-
负责人:GEORGE BATTAGLIA
-
依托单位:
Serotonin Reuptake Inhibitors and 5-HT1A Receptors
-
批准号:7812506
-
项目类别:
-
资助金额:$38.02万
-
财政年份:1995
-
负责人:GEORGE BATTAGLIA
-
依托单位:
Serotonin Reuptake Inhibitors and 5-HT1A Receptors
-
批准号:6844750
-
项目类别:
-
资助金额:$34.23万
-
财政年份:1995
-
负责人:GEORGE BATTAGLIA
-
依托单位:
SSRI TREATMENT OF PRENATAL COCAINE-INDUCED 5HT DEFICITS
-
批准号:6378551
-
项目类别:
-
资助金额:$34.2万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
SSRI TREATMENT OF PRENATAL COCAINE-INDUCED 5HT DEFICITS
-
批准号:6515495
-
项目类别:
-
资助金额:$34.2万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
SSRI TREATMENT OF PRENATAL COCAINE-INDUCED 5HT DEFICITS
-
批准号:6693443
-
项目类别:
-
资助金额:$34.2万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
IN UTERO COCAINE-INDUCED 5-HT DYSFUCTION IN PROGENY
-
批准号:2120239
-
项目类别:
-
资助金额:$11.72万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
IN UTERO COCAINE-INDUCED 5-HT DYSFUCTION IN PROGENY
-
批准号:2120238
-
项目类别:
-
资助金额:$9.5万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
IN UTERO COCAINE-INDUCED 5-HT DYSFUCTION IN PROGENY
-
批准号:3214381
-
项目类别:
-
资助金额:$11.18万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
SSRI TREATMENT OF PRENATAL COCAINE-INDUCED 5HT DEFICITS
-
批准号:6196115
-
项目类别:
-
资助金额:$34.2万
-
财政年份:1993
-
负责人:GEORGE BATTAGLIA
-
依托单位:
REGULATION OF DOPAMINE D-1 RECEPTORS/ADENYLATE CYCLASE
-
批准号:3052531
-
项目类别:
-
资助金额:$0.2万
-
财政年份:1985
-
负责人:GEORGE BATTAGLIA
-
依托单位:
海外基金